We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.27 | 0.83% | 32.92 | 32.91 | 32.92 | 32.93 | 32.44 | 32.56 | 1,845,492 | 17:57:01 |
By Andrea Figueras
Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types.
The Swiss pharmaceutical company said Tuesday that it has been granted marketing authorisation for Tecentriq SC, which reduces treatment time by approximately 80% compared with standard IV infusion.
The subcutaneous injections take between four and eight minutes, while until now the treatment had been given directly into patients' veins by IV infusion, which takes approximately 30-60 minutes.
Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer, Roche said.
The company is also working closely with several providers in Europe to include Tecentriq SC in cancer homecare initiatives where possible.
The injections can also be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient's home, depending on national regulations and health systems.
Write to Andrea Figueras at andrea.figueras@wsj.com
(END) Dow Jones Newswires
January 16, 2024 01:34 ET (06:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions